As a US government organization funded by the taxpayers, one would think that NASA is one of the most well-funded bodies in the world. However, it turns out that the space agency is far too broke to send people to Mars, contradicting what the Trump administration recently touted. Now, the only hope of humanity becoming a multi-planet species is SpaceX, which does have money.
There’s no denying that an endeavor like sending people to Mars would be a costly one and with the US political climate being what it is, committing resources to something that a lot of people believe is non-essential would be incredibly unpopular. In the case of NASA, the agency recently admitted during a meeting that even landing on Mars is beyond them.
"I can't put a date on humans on Mars, and the reason really is the other piece is, at the budget levels we described, this roughly 2 percent increase, we don’t have the surface systems available for Mars," William H. Gerstenmaier, the head of human spaceflight at NASA said. "And that entry, descent and landing is a huge challenge for us for Mars."
As Ars Technica notes, there were plenty of skeptics and naysayers who doubted that NASA even had the time or the capability to send people to Mars when the goal was announced. After this admission, those people just got, even more, ammunition to hurl towards the space agency.
For the most part, it would seem that some of the biggest obstacles that prevent the US space agency from achieving such a goal are the costs that its current rocket technology would incur. Unlike what SpaceX has already achieved, NASA does not have reusable rockets.
This would make launches incredibly expensive, and landing on Mars would be out of the question. Basically, as of this moment, Elon Musk’s private space company is the best hope that humanity has.


NASA Partners with Katalyst to Save Swift Observatory with Innovative Docking Mission
NASA Artemis II: First Crewed Moon Mission Since Apollo Takes Four Astronauts on 10-Day Lunar Journey
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
SpaceX Delays Starship V3 Launch Ahead of Potential Record IPO
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission
FDA Pilot Program Eases Rules for Nicotine Pouch Makers
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 



